Lnc-PINK regulation of innate immunity in lung epithelial cells
Lnc-PINK对肺上皮细胞先天免疫的调节
基本信息
- 批准号:10365976
- 负责人:
- 金额:$ 18.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-05 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:Acute Respiratory Distress SyndromeAntiviral AgentsCell physiologyDataDevelopmentDrug TargetingEpidemicEpithelialEpithelial CellsGene ExpressionGoalsHost DefenseHumanInflammasomeIntegration Host FactorsLungMediatingMessenger RNAModelingMolecularMolecular CloningMutationNatural ImmunityNucleotidesPINK1 genePeriodicityPharmacologyPneumoniaProteinsRegulationRespiratory SystemRoleTXNIP geneTestingTherapeutic InterventionTranscriptUntranslated RNAViralViral Drug ResistanceViral ProteinsViral Vaccinesbasedefense responsefirst responderinfluenza infectioninfluenzavirusmortalitynovelpandemic diseaserespiratory infection virusrespiratory pathogenrespiratory virustranscriptome sequencing
项目摘要
PROJECT SUMMARY
The influenza virus infects the respiratory tract and may result in acute respiratory distress syndrome and
pneumonia associated with a high mortality rate. The long-term goal of this project is to understand the
molecular mechanisms how the lung epithelial cells responds to and restricts respiratory virus infection. Innate
immunity is the first responder to respiratory pathogen invasion and provides the first line of defense in the
lung. Thus enhancing the host defense response against respiratory virus by targeting lung epithelial host
factors is a strategy to restrict respiratory virus infection regardless of any viral changes. Long non-coding
RNAs (lncRNAs) are mRNA-like transcripts with a size of > 200 nucleotides, but that do not encode proteins
and are involved in diverse cellular processes including innate immunity. Through RNA sequencing analysis
and molecular cloning, we have identified a novel lncRNA transcript, lnc-PINK1-2:5 in lung epithelial cells that
reduces influenza virus infection and up-regulates the expression of thioredoxin interacting protein (TXNIP)
that activates NLRP3 inflammasomses. Based on this preliminary data, we hypothesized that lnc-PINK1-2:5
restricts respiratory virus infection by activating NLRP3 inflammasomes via upregulating TXNIP gene
expression in lung epithelial cells. Aim I will establish the functional roles of lnc-PINK1-2:5 in influenza virus
infection of human lung epithelial cells. Aim II will delineate the molecular mechanisms of lnc-PINK1-2:5-
mediated restriction of influenza virus in human lung epithelial cells.
项目总结
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
MicroRNA-9-1 Attenuates Influenza A Virus Replication via Targeting Tankyrase 1.
- DOI:10.1159/000532063
- 发表时间:2023
- 期刊:
- 影响因子:5.3
- 作者:
- 通讯作者:
SNHG15 aids SARS-CoV-2 entry via RABL2A.
- DOI:10.1080/15476286.2023.2241755
- 发表时间:2023-01
- 期刊:
- 影响因子:4.1
- 作者:Pushparaj, Samuel;Gandikota, Chaitanya;Vaddadi, Kishore;Liang, Yurong;Liu, Lin
- 通讯作者:Liu, Lin
Regulation of influenza A virus infection by Lnc-PINK1-2:5.
- DOI:10.1111/jcmm.17249
- 发表时间:2022-04
- 期刊:
- 影响因子:5.3
- 作者:Pushparaj S;Zhu Z;Huang C;More S;Liang Y;Lin K;Vaddadi K;Liu L
- 通讯作者:Liu L
Axin1: A novel scaffold protein joins the antiviral network of interferon.
- DOI:10.1111/mmi.14995
- 发表时间:2022-12
- 期刊:
- 影响因子:3.6
- 作者:Guo, Yujie;Bamunuarachchi, Gayan;Vaddadi, Kishore;Zhu, Zhengyu;Gandikota, Chaitanya;Ahmed, Kainat;Pushparaj, Samuel;More, Sunil;Xiao, Xiao;Yang, Xiaoyun;Liang, Yurong;Mukherjee, Sanjay;Baviskar, Pradyumna;Huang, Chaoqun;Li, Shitao;Oomens, Antonius G. P.;Metcalf, Jordan Patrick;Liu, Lin
- 通讯作者:Liu, Lin
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LIN LIU其他文献
LIN LIU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LIN LIU', 18)}}的其他基金
Oklahoma Center for Respiratory and Infectious Diseases
俄克拉荷马州呼吸和传染病中心
- 批准号:
10628212 - 财政年份:2023
- 资助金额:
$ 18.7万 - 项目类别:
Oklahoma Center for Respiratory and Infectious Diseases
俄克拉荷马州呼吸和传染病中心
- 批准号:
10215542 - 财政年份:2013
- 资助金额:
$ 18.7万 - 项目类别:
Oklahoma Center for Respiratory and Infectious Diseases
俄克拉荷马州呼吸和传染病中心
- 批准号:
8686887 - 财政年份:2013
- 资助金额:
$ 18.7万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 18.7万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 18.7万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 18.7万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 18.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 18.7万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 18.7万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 18.7万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 18.7万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 18.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 18.7万 - 项目类别:














{{item.name}}会员




